Donisi Health Overview
Donisi Health is a medical technology company providing user-friendly in-home health detection solutions for patients with congestive heart failure (CHF) and other chronic diseases. Donisi enables a user-friendly preemptive approach to cardiac and pulmonary health monitoring in the home, helping to optimize the continuum of care for patients with CHF and other chronic diseases and avoid unnecessary rehospitalization. Based on Donisi's FDA-cleared technology and backed by 11 granted patents, Donisi's contact-free health detection works free from wires, wearables, and patches. The company's patented AI-based system detects and analyzes multiple health bio-indicators simultaneously, delivering clinically meaningful insights and notifications of changes in key health indicators. Donisi's clinically validated contact-free technology can remotely detect signs of pulmonary congestion and additional parameters key for heart failure exacerbation detection in the home.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Donisi Health Gets FDA's De Novo Clearance for Its Gili Biosensor System
Donisi Health has received FDA authorization to market its Gili biosensor system. The device uses an optical sensor and software algorithms to gather and analyze video data to estimate pulse rate, heart rate, respiratory rate, and breathing rates. The system is indicated for use by healthcare professionals in medical care settings or for clinical research purposes. The FDA has classified the device as hardware and software for optical camera-based measurement of vital signs.
Customers
growth-positive
Study Demonstrates Efficacy of Contact-Free Tech for Pulmonary Congestion Detection at Home
Donisi Health, a MedTech company, announced the results of a clinical study demonstrating the efficacy of its contact-free technology for detecting pulmonary congestion in congestive heart failure (CHF) patients. The study, presented at the American College of Cardiologys annual Scientific Session, showed that Donisis remote monitoring solution can detect key health biomarkers such as pulmonary congestion at home, potentially preventing unnecessary hospital readmissions. The study assessed Donisis Gili Pro BioSensor, which achieved a sensitivity and specificity of 0.91 and an accuracy of 91%. The companys AI-based technology can provide medical-grade monitoring for pulmonary congestion, offering a novel approach for at-home monitoring. The study was conducted in collaboration with the Department of Cardiology at the Tel Aviv Sourasky Medical Center.
Customers
growth-positive
Donisi Health Presents Data at ACC22 Demonstrating Accuracy of a Contact-Free Medical Device that Detects Pulmonary Congestion in CHF Patients at Home
Donisi Health, a MedTech company, announced the results of a clinical study demonstrating the efficacy of its contact-free technology for detecting pulmonary congestion in congestive heart failure (CHF) patients. The study presented at the American College of Cardiologys annual Scientific Session showed that Donisis remote monitoring solution could detect key health biomarkers such as pulmonary congestion at home, potentially preventing unnecessary patient re-hospitalization. The study confirmed that Donisis contact-free infrared optical solution could provide medical-grade monitoring for pulmonary congestion, offering a novel approach for at-home monitoring of CHF patients. Donisis technology detects and analyzes multiple health bio-indicators simultaneously, providing a platform solution for managing patients with multiple chronic conditions and co-morbidities. The company plans to expand the clinical scope of its technology and seek clearance for at-home identification of pulmonary congestion.
Customers
growth-positive
Israeli startup Donisi Health lands De Novo for AI-enabled contactless monitor
Donisi Health, a Tel Aviv-based maker of contactless health monitoring products, has received FDA De Novo clearance for its Gili Pro BioSensor system. The system uses optical sensors and AI algorithms to remotely monitor surface-level micro-vibrations associated with the workings of internal organs. Donisi plans to expand the clinical scope of the Gili Pro and has already undergone the FDA Pre Submission process for the identification of atrial fibrillation. The company aims to bridge the continuum of care from hospital to home. The Gili Pro has maintained medical-grade accuracy across different body shapes and skin tones. The device can be controlled through a mobile application. The prospect of remote continuous vital-sign monitoring is especially desirable amid the pandemic. Donisis technology is recognized and cleared by the FDA.
Expand
growth-positive
250 companies and $6.5 billion: An in-depth look at Israel's healthtech industry
Israeli healthcare startups are reinventing business models and elevating the industry. The article discusses the growth and innovation in the Israeli healthcare startup ecosystem. It highlights the key areas of Digital Health, Medical Devices, and Biopharma, and how these sectors are evolving their business models. Digital Health startups are shifting towards providing end-to-end solutions, while Medical Device startups are adapting to the Value Based Care model. Biopharma startups are focusing on precision medicine and drug R&D. The article emphasizes the growth and value generated by Israeli healthcare startups, with a combined funding of $6.5 billion. The analysis was conducted by Pitango HealthTech Fund.
CustomersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $27.2M |
| Last funding | Undisclosed |
| Stage | B |
| Rounds | 6 |
| Investors | 5 |
Team Members
5
Employees: 1-10
Web & Social Links
| Website | donisihealth.com/ |
| Careers | Careers page |
| App Store | App Store |
Locations
HaNechoshet Street 6, Tel Aviv, Israel
California, USA
Photos & Videos
3 item(s)
